AbbVie Signs a Worldwide Non-Exclusive License Agreement for Humira’s (adalimumab) Patent Rights with Pfizer

 AbbVie Signs a Worldwide Non-Exclusive License Agreement for Humira’s (adalimumab) Patent Rights with Pfizer

AbbVie Signs a Worldwide Non-Exclusive License Agreement for Humira’s (adalimumab) Patent Rights with Pfizer

Shots:

  • Pfizer to get worldwide IPR for Humira in the US and other countries and will pay royalties on sales to AbbVie
  • Humira’s the US license right will begin from 20 Nov, 2023 and will be available in EU post EMA approval
  • Humira (adalimumab) a mAb helps in blocking TNF protein, approved for 14 global indications and 10 the US indications

Click here to read full press release/ article | Ref: AbbVie | Image: AbbVie

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post